Холандија - Холандски - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

beclometasondipropionaat 0-water 100 µg/dosis ; formoterolfumaraat 2-water 6 µg/dosis samenstelling overeenkomend met ; formoterol 4,9 µg/dosis - inhalatiepoeder - lactose 1-water ; magnesiumstearaat (e 470b)

Холандија - Холандски - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

beclometasondipropionaat 0-water 200 µg/dosis ; formoterolfumaraat 2-water 6 µg/dosis samenstelling overeenkomend met ; formoterol 4,9 µg/dosis - inhalatiepoeder - lactose 1-water ; magnesiumstearaat (e 470b)

Белгија - Холандски - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

msd belgium bv-srl - levend, geattenueerd, varicella-zoster virus - poeder en oplosmiddel voor suspensie voor injectie - varicellavirus - varicella, live attenuated

Белгија - Холандски - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline biologicals sa-nv - levend, geattenueerd, mazelenvirus ; levend, geattenueerd, bofvirus ; levend, geattenueerd, rubellavirus ; levend, geattenueerd, varicella-zoster virus - poeder en oplosmiddel voor oplossing voor injectie - mazelenvirus; bofvirus; rubellavirus; varicellavirus - measles, combinations with mumps, rubella and varicella, live attenuated

Белгија - Холандски - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline biologicals sa-nv - levend, geattenueerd, mazelenvirus ; levend, geattenueerd, bofvirus ; levend, geattenueerd, rubellavirus ; levend, geattenueerd, varicella-zoster virus - poeder en oplosmiddel voor oplossing voor injectie - bofvirus; mazelenvirus; rubellavirus; varicellavirus - measles, combinations with mumps, rubella and varicella, live attenuated

Белгија - Холандски - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline biologicals sa-nv - levend, geattenueerd, varicella-zoster virus >= 2000 pfu - poeder en oplosmiddel voor oplossing voor injectie - varicellavirus - varicella, live attenuated

Белгија - Холандски - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline biologicals sa-nv - levend, geattenueerd, varicella-zoster virus >= 2000 pfu - poeder en oplosmiddel voor oplossing voor injectie - varicellavirus - varicella, live attenuated

Европска Унија - Холандски - EMA (European Medicines Agency)

laboratorios lesvi s.l. - dimethylfumaraat - multiple sclerose, relapsing-remitting - immunosuppressiva - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Европска Унија - Холандски - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artritis, reumatoïde - immunosuppressiva - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Европска Унија - Холандски - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - lupus erythematosus, systemisch - immunosuppressiva - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.